[PDF][PDF] Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer
Purpose Everolimus, an oral inhibitor of the mammalian target of rapamycin, has shown
antitumor activity. in gastric cancer in preclinical and phase l studies. This phase ll study
evaluated the efficacy and safety of everolimus in pretreated patients with advanced gastric
cancer. Patients and Methods; Patients with advanced gastric cancer vvho experienced
progression despite prior chemotherapy received everolimus 10 mg orally daily until
disease progression or study discontinuation. The primary end point was disease control …
antitumor activity. in gastric cancer in preclinical and phase l studies. This phase ll study
evaluated the efficacy and safety of everolimus in pretreated patients with advanced gastric
cancer. Patients and Methods; Patients with advanced gastric cancer vvho experienced
progression despite prior chemotherapy received everolimus 10 mg orally daily until
disease progression or study discontinuation. The primary end point was disease control …